These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 11304580)
1. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Nagy N; Brenner C; Markadieu N; Chaboteaux C; Camby I; Schäfer BW; Pochet R; Heizmann CW; Salmon I; Kiss R; Decaestecker C Lab Invest; 2001 Apr; 81(4):599-612. PubMed ID: 11304580 [TBL] [Abstract][Full Text] [Related]
2. Down-regulation of S100A2 in lymph node metastases of head and neck cancer. Zhang X; Hunt JL; Shin DM; Chen ZG Head Neck; 2007 Mar; 29(3):236-43. PubMed ID: 17123307 [TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma. Tsai WC; Tsai ST; Jin YT; Wu LW Mol Cancer Res; 2006 Aug; 4(8):539-47. PubMed ID: 16908593 [TBL] [Abstract][Full Text] [Related]
4. The Ca2+-binding S100A2 protein is differentially expressed in epithelial tissue of glandular or squamous origin. Nagy N; Hoyaux D; Gielen I; Schäfer BW; Pochet R; Heizmann CW; Kiss R; Salmon I; Decaestecker C Histol Histopathol; 2002 Jan; 17(1):123-30. PubMed ID: 11813862 [TBL] [Abstract][Full Text] [Related]
5. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Smith SL; Gugger M; Hoban P; Ratschiller D; Watson SG; Field JK; Betticher DC; Heighway J Br J Cancer; 2004 Oct; 91(8):1515-24. PubMed ID: 15467767 [TBL] [Abstract][Full Text] [Related]
6. Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Choi J; Lee MK; Oh KH; Kim YS; Choi HY; Baek SK; Jung KY; Woo JS; Lee SH; Kwon SY Tumori; 2011; 97(2):196-202. PubMed ID: 21617715 [TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of S100A2 and p63 in esophageal carcinoma. Cao LY; Yin Y; Li H; Jiang Y; Zhang HF World J Gastroenterol; 2009 Sep; 15(33):4183-8. PubMed ID: 19725154 [TBL] [Abstract][Full Text] [Related]
8. The p53-S100A2 Positive Feedback Loop Negatively Regulates Epithelialization in Cutaneous Wound Healing. Pan SC; Li CY; Kuo CY; Kuo YZ; Fang WY; Huang YH; Hsieh TC; Kao HY; Kuo Y; Kang YR; Tsai WC; Tsai ST; Wu LW Sci Rep; 2018 Apr; 8(1):5458. PubMed ID: 29615682 [TBL] [Abstract][Full Text] [Related]
9. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Feng G; Xu X; Youssef EM; Lotan R Cancer Res; 2001 Nov; 61(21):7999-8004. PubMed ID: 11691825 [TBL] [Abstract][Full Text] [Related]
10. Diminished expression of S100A2, a putative tumour suppressor, is an independent predictive factor of neck node relapse in laryngeal squamous cell carcinoma. Almadori G; Bussu F; Galli J; Rigante M; Lauriola L; Michetti F; Maggiano N; Schafer BW; Heizmann CW; Ranelletti FO; Paludetti G J Otolaryngol Head Neck Surg; 2009 Feb; 38(1):16-22. PubMed ID: 19344608 [TBL] [Abstract][Full Text] [Related]
11. Regulation of S100A2 expression by TGF-β-induced MEK/ERK signalling and its role in cell migration/invasion. Naz S; Ranganathan P; Bodapati P; Shastry AH; Mishra LN; Kondaiah P Biochem J; 2012 Oct; 447(1):81-91. PubMed ID: 22747445 [TBL] [Abstract][Full Text] [Related]
12. S100A2 in cancerogenesis: a friend or a foe? Wolf S; Haase-Kohn C; Pietzsch J Amino Acids; 2011 Oct; 41(4):849-61. PubMed ID: 20521072 [TBL] [Abstract][Full Text] [Related]
13. Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma. Sugiyama T; Ozono S; Miyake H Anticancer Res; 2020 Nov; 40(11):6337-6343. PubMed ID: 33109571 [TBL] [Abstract][Full Text] [Related]
14. S100A expression in normal corneal-limbal epithelial cells and ocular surface squamous cell carcinoma tissue. Li J; Riau AK; Setiawan M; Mehta JS; Ti SE; Tong L; Tan DT; Beuerman RW Mol Vis; 2011; 17():2263-71. PubMed ID: 21897749 [TBL] [Abstract][Full Text] [Related]
15. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. Mueller A; Schäfer BW; Ferrari S; Weibel M; Makek M; Höchli M; Heizmann CW J Biol Chem; 2005 Aug; 280(32):29186-93. PubMed ID: 15941720 [TBL] [Abstract][Full Text] [Related]
16. S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma. Imazawa M; Hibi K; Fujitake S; Kodera Y; Ito K; Akiyama S; Nakao A Anticancer Res; 2005; 25(2B):1247-50. PubMed ID: 15865073 [TBL] [Abstract][Full Text] [Related]
17. S100A2 induces metastasis in non-small cell lung cancer. Bulk E; Sargin B; Krug U; Hascher A; Jun Y; Knop M; Kerkhoff C; Gerke V; Liersch R; Mesters RM; Hotfilder M; Marra A; Koschmieder S; Dugas M; Berdel WE; Serve H; Müller-Tidow C Clin Cancer Res; 2009 Jan; 15(1):22-9. PubMed ID: 19118029 [TBL] [Abstract][Full Text] [Related]
18. Expression of S100A2 and S100B proteins in epithelial tumors of the skin. Park HR; Min SK J Cutan Pathol; 2003 Jul; 30(6):373-8. PubMed ID: 12834486 [TBL] [Abstract][Full Text] [Related]
19. Identification of S100A2 as a target of the DeltaNp63 oncogenic pathway. Hibi K; Fujitake S; Takase T; Kodera Y; Ito K; Akiyama S; Shirane M; Nakao A Clin Cancer Res; 2003 Sep; 9(11):4282-5. PubMed ID: 14519656 [TBL] [Abstract][Full Text] [Related]
20. S100A2, a potential marker for early recurrence in early-stage oral cancer. Tsai ST; Jin YT; Tsai WC; Wang ST; Lin YC; Chang MT; Wu LW Oral Oncol; 2005 Apr; 41(4):349-57. PubMed ID: 15792606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]